Nuvation Bio Inc. — Q1 2021 Form 10-Q
Reporting period: Three months ended March 31, 2021; filed May 17, 2021. Financial statements are unaudited. Unless otherwise noted, amounts below are in U.S. dollars.
Business context and reporting period
Nuvation Bio is a clinical-stage oncology biopharmaceutical company with no commercially approved products and no revenue. Its lead candidate, NUV-422, entered a Phase 1/2 trial for high-grade glioma in December 2020. The February 10, 2021 merger with Panacea Acquisition Corp. was accounted for as a reverse recapitalization; Legacy Nuvation Bio is the accounting predecessor.
Key financial metrics
| Metric | Q1 2021 | Q1 2020 or prior balance-sheet date |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $15.9 million | $7.3 million |
| General and administrative expense | $4.6 million | $1.9 million |
| Total operating expenses | $20.5 million | $9.2 million |
| Net loss | $20.4 million | $8.7 million |
| Basic and diluted loss per share | $0.12 | $0.10 |
| Cash used in operating activities | $14.7 million | $8.7 million |
| Cash and cash equivalents | $638.9 million | $29.8 million at December 31, 2020 |
| Marketable securities | $185.8 million | $186.0 million at December 31, 2020 |
| Total liabilities | $25.7 million, including $15.6 million warrant liability | $6.7 million at December 31, 2020 |
Cash, cash equivalents and marketable securities totaled $824.7 million at March 31, 2021. Cash provided by financing activities was $625.0 million, principally from the merger and related financing; the merger note reports net proceeds of $622.4 million. No debt balance is reported. Gross profit and operating margins are not meaningful because the company has no revenue.
Material changes versus the prior comparable period
- Net loss increased $11.7 million year over year as operating expenses rose $11.3 million.
- R&D expense increased $8.6 million, primarily from $4.3 million of higher third-party research and manufacturing costs, $3.7 million of stock issued as consideration for acquired in-process R&D, and higher personnel costs.
- G&A expense increased $2.7 million, driven mainly by personnel, insurance, taxes and professional fees, including costs associated with becoming a public company.
- Operating cash use increased $6.0 million year over year. The substantial increase in cash and equity followed the February merger and PIPE/forward-purchase financing.
Outlook, commentary and risks
- Management expects operating losses and negative operating cash flows for the foreseeable future. It believes available cash and marketable securities will fund commitments for at least 12 months after issuance of the financial statements; this depends on assumptions about development costs and timing.
- Management expected top-line data from the Phase 1 portion of the NUV-422 trial in 2022, multiple additional Phase 1 trial initiations through 2022, and up to five additional IND submissions across the pipeline over six years.
- COVID-19 had not materially affected operations to date, but could disrupt trials, enrollment, suppliers, contract manufacturers and research partners.
- Key risks include clinical and regulatory failure or delay, reliance on third-party research and manufacturing, limited operating history, need for future funding, competition, and intellectual-property uncertainty. The company reported only two issued patents as of March 31, 2021.
- Warrants are classified as liabilities and remeasured at fair value; the Q1 fair-value change produced a $0.3 million loss. The valuation uses Level 3 inputs.
- The filing reports no pending significant legal proceedings expected to materially affect financial position. Management concluded disclosure controls were effective at March 31, 2021; it also says a prior Panacea material weakness concerning warrant accounting was remediated following the merger.
Important facts for investors to verify
- Whether NUV-422 trial enrollment, safety and data timing remain consistent with the stated 2022 expectation.
- How the company’s cash runway changes as clinical programs, hiring and public-company costs expand.
- The reconciliation and presentation of merger financing proceeds, including the $625.0 million cash-flow figure and $622.4 million net-proceeds figure.
- The potential future dilution from outstanding options, warrants and equity-plan reserves, and the effects of the dual-class share structure and founder voting rights.
- Whether the warrant-liability valuation assumptions or accounting judgments change materially in later periods.